Jefferies Hikes Regeneron Price Target to $930 After Expanded Sanofi Deal

Key Facts

1Jefferies raised its price target for Regeneron to $930.00 from $870.00.

2Sanofi will pay Regeneron $1.00 billion upfront to develop four new long-acting antibodies.

3Regeneron could receive up to $7.00 billion in milestone payments based on development and commercial goals.

Jefferies raised its price target for Regeneron to $930.00 from $870.00 on October 1, 2026. The revision follows an announcement that Sanofi will pay Regeneron $1.00 billion upfront to develop four new long-acting antibodies, Reuters reported. The expanded partnership focuses on next-generation inflammatory treatments to secure long-term revenue streams.

Regeneron could receive up to $7.00 billion in additional milestone payments based on development and commercial goals, according to Financial Modeling Prep. In equity markets, SNYNF closed at $80.76 on September 30, 2026. The deal is designed to strengthen the company's drug pipeline as it prepares for future competition in the pharmaceutical landscape.